肺癌疫苗的研究进展(5)
16.Bixby DL, Yannelli JR. CD80 expression in an HLA-A2-positive human non-small cell lung cancer cell line enhances tumor-specific cytotoxicity of HLA-A2-positive T cells derived from a normal donor and a patient with non-small cell lung cancer. Int J Cancer 1998 Dec 9;78(6):685-94
17.Kim JJ, Trivedi N, Wilson DM, et al. molecular and immunological analysis of genetic prostate specific antigen(PSA) vaccine. Oncogene, 1998;17:3125.
18.林星石，费丽华，李力，孙小华，袁玫。抗腺癌肿瘤疫苗对小鼠Lewis肺癌的主动特异性免疫治疗。军医进修学院学报，2000,21(4):270-272.
19.Nair SK, Synder D, Douse BT. Regression of tumors in mice vaccinated with professional antigen-presenting cells pulsed with tumor extracts. Int J Cancer, 1997,70:706.
20.Becker Y. Dendritic cell activity against primary tumors: an overview. In Vivo, 1993;7:187.
21.Wright-Browner V, McClain KL, Talpaz M. physiology and pathophysiology of dendritic cells. Human Pathol, 1997,5:563.
22.李明松，袁爱力，陈学清。树突状细胞诱导的细胞毒T淋巴细胞抑制移植瘤细胞增殖。肿瘤，1999,19(5):277-280.
23.Guo YJ, Che XY, Shen F, et al. Effective tumor vaccines generated by in vitro modification of tumor cells with cytokines and bispecific monoclonal antibodies. Nat Med 1997 Apr;3(4):451-455.
24.Divgi CR, welt S, Kris M. Phase Ⅰ and imaging trial of indium Ⅲ labeled anti-epidermal growth factor receptor monoclonal antibody 225 in patients with squamous cell lung carcinoma. J Natl Cancer Inst, 1991,83:97-104.
25.O'Brien ME, Saini A, Smith IE, et al. A randomized phase II study of SRL172 (Mycobacterium vaccine) combined with chemotherapy in patients with advanced inoperable non-small-cell lung cancer and mesothelioma. Br J Cancer 2000 Oct;83(7):853-7., http://www.100md.com(钟文昭、黄邵洪、吴一龙、谷力加、翁毅敏、冯卫能、程超)
17.Kim JJ, Trivedi N, Wilson DM, et al. molecular and immunological analysis of genetic prostate specific antigen(PSA) vaccine. Oncogene, 1998;17:3125.
18.林星石，费丽华，李力，孙小华，袁玫。抗腺癌肿瘤疫苗对小鼠Lewis肺癌的主动特异性免疫治疗。军医进修学院学报，2000,21(4):270-272.
19.Nair SK, Synder D, Douse BT. Regression of tumors in mice vaccinated with professional antigen-presenting cells pulsed with tumor extracts. Int J Cancer, 1997,70:706.
20.Becker Y. Dendritic cell activity against primary tumors: an overview. In Vivo, 1993;7:187.
21.Wright-Browner V, McClain KL, Talpaz M. physiology and pathophysiology of dendritic cells. Human Pathol, 1997,5:563.
22.李明松，袁爱力，陈学清。树突状细胞诱导的细胞毒T淋巴细胞抑制移植瘤细胞增殖。肿瘤，1999,19(5):277-280.
23.Guo YJ, Che XY, Shen F, et al. Effective tumor vaccines generated by in vitro modification of tumor cells with cytokines and bispecific monoclonal antibodies. Nat Med 1997 Apr;3(4):451-455.
24.Divgi CR, welt S, Kris M. Phase Ⅰ and imaging trial of indium Ⅲ labeled anti-epidermal growth factor receptor monoclonal antibody 225 in patients with squamous cell lung carcinoma. J Natl Cancer Inst, 1991,83:97-104.
25.O'Brien ME, Saini A, Smith IE, et al. A randomized phase II study of SRL172 (Mycobacterium vaccine) combined with chemotherapy in patients with advanced inoperable non-small-cell lung cancer and mesothelioma. Br J Cancer 2000 Oct;83(7):853-7., http://www.100md.com(钟文昭、黄邵洪、吴一龙、谷力加、翁毅敏、冯卫能、程超)